Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Wednesday,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Several other equities analysts have also recently commented on HUMA. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $13.71.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $1.96 on Wednesday. The stock has a 50-day simple moving average of $3.61 and a 200-day simple moving average of $4.51. The stock has a market capitalization of $246.68 million, a P/E ratio of -1.46 and a beta of 1.36. Humacyte has a 1 year low of $1.76 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. Analysts predict that Humacyte will post -1.27 earnings per share for the current year.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently modified their holdings of the company. Endowment Wealth Management Inc. grew its position in shares of Humacyte by 3.6% in the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after purchasing an additional 3,590 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Humacyte by 18.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock worth $138,000 after buying an additional 4,327 shares during the period. Beacon Pointe Advisors LLC boosted its position in shares of Humacyte by 33.3% in the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after acquiring an additional 5,000 shares during the period. Rhumbline Advisers grew its stake in shares of Humacyte by 4.6% in the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock worth $578,000 after acquiring an additional 5,005 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in Humacyte by 25.3% during the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock worth $132,000 after acquiring an additional 5,293 shares during the period. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.